vedolizumab

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Lilly, Foghorn part ways; Wave’s FDA-approved plans
  The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
  biopharma_dive · 2d ago
• Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
  Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.
  fiercebiotech · 23d ago
• Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
  Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.
  fiercebiotech · 25d ago
• Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
  Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
  fiercebiotech · 25d ago
• 5 NextGen winners who went public this year (and which ones are hiring)
  BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.
  biospace · 1mo ago
• Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
  Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…
  fiercebiotech · 2mo ago
• Abivax shares surge as worries subside over immune drug’s cancer risk
  According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
  biopharma_dive · 3mo ago
• cAMPfield lands $180M to build gut disease drug
  The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
  biopharma_dive · 3mo ago
• AbiVax falls as safety worries cloud ‘landmark’ immune drug results
  A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
  biopharma_dive · 4mo ago
• Odyssey, on second try, snags $279M in an IPO
  After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…
  biopharma_dive · 4mo ago